Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 24 Apr 2023
Canada: The Journal of Psychiatric Research recently reported that childhood cat ownership, particularly with rodent-hunting cats,.
Read Full NewsIn high-risk low-grade glioma, starting with temozolomide or radiotherapy yields similar survival.
Researchers aim to evaluate the effectiveness of ASCT as consolidation therapy for patients with advanced-stage natural killer/T-cell lymphoma who have attained their first complete remission.
1.
Some low-grade prostate cancers carry higher risks than biopsy suggests
2.
NHS Offers Targeted Radiotherapy for Early Prostate Cancer
3.
There is a 40% reduction in the risk of 9 cancers with good cardiorespiratory fitness.
4.
Tumor characteristics found to differ for melanomas in children, teens and young adults
5.
Alecensa (alectinib) Offers Hope for Certain Patients With ALK Positive NSCLC
1.
Understanding Phyllodes Tumor: Symptoms, Diagnosis, and Treatment Options
2.
Know About Lymphangioma: Symptoms, Causes, and Treatments
3.
Personalized Cancer Vaccines: The Next Frontier in Precision Oncology
4.
What Is May-Hegglin Anomaly? Understanding this Rare Blood Disorder
5.
Unlocking the Mysteries of Rhabdomyoma: A New Hope for Treatment
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Unmet Needs in ALK Positive NSCLC- The Challenges in the Current Care
2.
From Relapse to Remission : Chasing the Invisible and Redefining Long-Term Survival in Adult R/R B-Cell ALL
3.
Current Scenario of Blood Cancer- Further Discussion on Genomic Testing & Advancement in Diagnosis and Treatment
4.
Updates on the First Line Management of ALK+ NSCLC
5.
A Conclusive Discussion on CROWN Trial and the Dawn of a New Era in Frontline Management of ALK+ NSCLC
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge